Related Experiment Video
Updated: Apr 8, 2026
![PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F57243.jpg&w=3840&q=50)
PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke
Published on: June 14, 2018
P2X7 receptor and neuroinflammation in neurodegenerative disorders: an autoradiography study with [ 18 F]JNJ-64413739
Abhishekh Hulegar Ashok1,2, Sophie Field3, Nisha Kuzhuppilly Ramakrishnan3
1Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust.
Background:
Neuroinflammation plays a crucial role in neurodegenerative disorders such as Alzheimer's disease. The P2X7 receptor (P2X7R), expressed on microglia, is involved in neuroinflammatory responses. Despite evidence of P2X7R upregulation in Alzheimer's disease models, its role in human Alzheimer's disease remains unclear. The PET radioligand [ 18 F]JNJ-64413739 enables the assessment of P2X7R distribution in post-mortem Alzheimer's disease brain tissue.
Methods:
Post-mortem brain tissue from Alzheimer's disease and control subjects was obtained. [ 18 F]JNJ-64413739 was synthesised and applied to tissue sections from the temporal and parietal cortex. Autoradiography was conducted with and without the P2X7R antagonist JNJ54173717.
Results:
[ 18 F]JNJ-64413739 binding was observed across all brain regions, with effective blocking confirming specificity. No significant differences were found between Alzheimer's disease and controls in the temporal ( P = 0.84) or parietal cortex ( P = 0.90) in the first experiment. The second experiment, using a modified protocol also did not reveal a significant difference between controls and Alzheimer's disease in either temporal ( P = 0.66) or parietal cortex ( P = 0.38). White matter exhibited significantly higher binding than grey matter ( P < 0.01), but no disease-specific differences were noted.
Conclusion:
This study demonstrates P2X7 receptor-specific binding of [ 18 F]JNJ-64413739 but finds no significant differences between post-mortem tissue of Alzheimer's disease cases and controls. These findings suggest that while the tracer shows promising in vitro characteristics, the role of P2X7R in Alzheimer's disease pathology and its utility as a biomarker require further validation through in vivo imaging studies across disease stages.
Insights
This study utilized the PET radioligand [18F]JNJ-64413739 to assess P2X7 receptor (P2X7R) binding in Alzheimer
Area of Science:
- Neuroscience
- Molecular Biology
- Radiochemistry
Background:
- Neuroinflammation is a key factor in neurodegenerative diseases like Alzheimer's disease.
- The P2X7 receptor (P2X7R), found on microglia, contributes to neuroinflammatory responses.
- While P2X7R is upregulated in Alzheimer's disease models, its role in human Alzheimer's disease is not fully understood.
Purpose of the Study:
- To evaluate the binding characteristics of the PET radioligand [18F]JNJ-64413739 in post-mortem human brain tissue.
- To investigate the distribution and potential differences in P2X7R expression between Alzheimer's disease and control subjects.
- To assess the utility of [18F]JNJ-64413739 as a potential biomarker for Alzheimer's disease.
Main Methods:
- Post-mortem brain tissue from Alzheimer's disease and control individuals was analyzed.
- [18F]JNJ-64413739 was synthesized and applied to temporal and parietal cortex tissue sections.
- Autoradiography was performed with and without the P2X7R antagonist JNJ54173717 to confirm specificity.
Main Results:
- The PET radioligand [18F]JNJ-64413739 demonstrated specific binding to P2X7R.
- No significant differences in P2X7R binding were observed between Alzheimer's disease and control subjects in either the temporal or parietal cortex.
- White matter showed higher binding than grey matter, but this difference was not disease-specific.
Conclusions:
- The PET tracer [18F]JNJ-64413739 exhibits promising in vitro characteristics for P2X7R binding.
- This study found no significant differences in P2X7R binding in post-mortem brain tissue from Alzheimer's disease patients compared to controls.
- Further in vivo imaging studies are necessary to validate the role of P2X7R in Alzheimer's disease pathology and its potential as a biomarker.

